Friday, November 6, 2026
5:45 PM CT – 6:00 PM CT Registration & Dinner
6:00 PM CT – 7:30 PM CT: CME Symposium
Marriott Marquis Chicago
2121 South Prairie Avenue
Chicago, IL
Meeting Room: Great Lakes E
PRESENTING FACULTY
 |
Daniel Lachant, DO Associate Professor of Medicine University of Rochester Medical Center Rochester, New York |
 |
Murali Chakinala, MD Professor Division of Pulmonary and Critical Care Medicine The Lung Center in the Center for Advanced Medicine St. Louis, Missouri |
PROGRAM OVERVIEW
This evidence-based symposium explores the evolving landscape of pulmonary arterial hypertension (PAH) exploring the pathophysiological mechanisms underlying this complex disease process, updated hemodynamic diagnostic thresholds, and how these mechanisms inform targeted therapies. Participants will examine the symptoms, clinical signs, and diagnostic approaches to facilitate earlier recognition of PAH and reduce diagnostic delays. The program will include didactic presentations by renowned experts, an animation, and case-based discussions to apply the latest evidence and guidelines to develop individualized approaches including strategic escalation of PAH-targeted therapies based on disease severity, risk, and treatment response.
TARGET AUDIENCE
This activity is designed to meet the educational needs of cardiologists, pulmonologists, and related APPs.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize key mechanisms underlying endothelial dysfunction, smooth muscle proliferation, and right ventricular remodeling in PAH, and their relevance to therapeutic targets and disease trajectory
- Apply guideline-aligned algorithms to evaluate patients with unexplained dyspnea or suspected PAH, incorporating appropriate use of screening and diagnostic tools
- Incorporate trial data, safety considerations, and patient-specific factors when selecting therapies in accordance with guideline recommendations
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this live activity for a maximum of up to 1.5 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]
